US › Healthcare

Larimar Therapeutics Inc (LRMR)

US · Healthcare · Biotechnology

$4.11+3.27%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-29.6M
Profit YoY
-1.1%
EPS
$-0.31
EPS estimate
$-0.59

EPS came in at -0.31 against a street estimate of -0.59 — a beat of 47.5%.

Key statistics

Market cap
$396.8M
Forward P/E
0.0
P/B
2.51
Book value
$1.51
EPS (TTM)
$-2.12
52-week high
$6.42
52-week low
$2.71
50-day MA
$3.58
200-day MA
$3.90
Beta
0.84

Analyst view

Analysts rate Larimar Therapeutics Inc a strong buy (11 buy, 0 hold, 0 sell out of 11) with an average price target of $14.40.

Shareholding

Insiders
1.15%
Institutions
86.20%

Largest institutional holders

FundStake
Deerfield Management Co34.28%
Blue Owl Capital Holdings LP6.85%
BlackRock Inc3.61%
Millennium Management LLC3.49%
AIGH Capital Management, LLC2.89%
Driehaus Capital Management LLC2.82%
Vanguard Capital Management, LLC2.76%
Dafna Capital Management LLC1.95%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Larimar Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.